JCBR accepts only online submissions at http://jcbr.goums.ac.ir. Manuscripts should be submitted via completion of the article submission steps provided on the website.
Original research articles and case reports should not exceed 3500 words including tables and figures (excluding references).
Short communications should be restricted to 2000 words and not less than 500 words in length including one table and two figures (excluding reference). Short communication are short papers reporting new ideas, models, methods, hypotheses and results of complete small investigations.
Review articles are also peer-review and should not exceed 4500 words (excluding references).
Authors are responsible for the accuracy of data reported and references to others' works, including bibliographic citations, etc.
Manuscript files submission
All manuscripts must be typed single-spaced and include line and page numbers.
Title page information
The title page of papers should contain a running title with no more than 50 characters. Authors’ information should include name(s), addresses (Tel, Fax, and Email) and affiliations. Present the authors' affiliation addresses below the names. All affiliations should be given a number with a lower-case superscript letter immediately after the author's name and in front of the appropriate address.
A concise and factual abstract is required for all manuscripts (maximum 300 words). This section should include Introduction, Materials and Methods, Results and Conclusions. The Abstract should describe the main objective(s) of the study, explain how the study was done, including any model organisms used, without methodological detail, summarizes the main results and their significance. This section should not include citations and unncecessary abbreviations.
This section should include three to ten keywords representing the main content of the article, separated by commas.
Corresponding author is the primary contact responsible for handling correspondence at all pre- or post-publication stages. Phone numbers should include country and area code. In addition, email address and complete postal address of the corresponding author should be written in a section below the abstract. Name of the corresponding author should be mark with a single asterisk (*).
The introduction should provide background and objective of the study that allows readers outside the field to understand the purpose and significance of the study. It should define the problem addressed and why it is important in form of a brief literature review. State relevant controversies or disagreements in the subject of the study and conclude with a brief statement of the overall aim of the work.
Materials and Methods
This section should provide enough details that allow other skilled investigators to fully replicate the study. Specific information and/or protocols for new methods should be included in detail. If materials, methods, and protocols are well established, authors may cite articles where those protocols are described in detail, but the submission should include sufficient information to be understood independent of these references. Generic drug names should generally be used. When proprietary brands are used in research, include the brand names in parentheses Studies on humans or animal models and/or tissue or field sampling must include required Ethics statements from the relevant local or national authority. Cell lines must state the origin of the cell lines used. Submission of sequence data to databases: Novel nucleotide or protein sequence data must be deposited in the GenBank, EMBL or DDBJ databases and an accession number obtained before the paper can be accepted for publication. For each accession number cited in an article, authors should type the accession number in capital. This section should also contain the type of statistical analysis used, including a power calculation if appropriate.
This section should be written in past tense and include the findings of the study including and results of statistical analysis which must be included either in the text, tables and figures. Avoid duplicating the results provided in the text and tables. Discussion, speculation and data interpretation should be included in the discussion section and not in the results section.
This section should discuss the implications of the findings in in relation to previous related studies, point out limitations of the study. Authors should explain how the results relate to the hypothesis or objective of the study. Avoid extensive citations and discussion of published literature.
This section should provide the main conclusions and explain the importance and relevance of the study reported. Avoid introducing new findings in this section or reporting general conclusions or facts. This section could also highlight potential directions for future studies.
Tables should be designed as simple as possible with clear borders and not in form of an image. Cite tables in ascending numeric order upon first appearance in the text. Place each table in the manuscript immediately after the paragraph in which it is first cited. Label tables (e.g., “Table 1”) and provide brief description above the table. Place legends, footnotes, and other text below the table.
Cite figures in ascending numeric order upon first appearance in the manuscript file. Label figures (e.g., ‘’Figure 1) and provide a concise, descriptive title and captions below the figure. The caption may also include a legend as needed. Figures should be in high quality and figure captions should be mentioned in the text immediately after the paragraph in which the figure is first cited. Authors are responsible for obtaining permission from the copyright holder to reproduce figures (or tables) that have previously been published elsewhere.
This section should include the name of individuals who contributed to the study or the article but do not meet the criteria for authorship including anyone who provided professional writing services or materials. Authors should obtain permission to acknowledge from all those mentioned in the Acknowledgements section. If you do not have anyone to acknowledge, please write "Not applicable" in this section. The Acknowledgments of people, grants, funds, etc should be brief.
All references, including URLs, must be numbered consecutively, in square brackets (e.g., ‘’ Several studies indicated the increasing rate of antibiotic resistance ’’), in the order in which they are cited in the text, followed by any in tables or legends. Acceptable sources include published or accepted manuscripts and manuscripts on preprint servers. Do not cite unavailable and unpublished work. References must be listed at the end of the manuscript and numbered in the order of their appearance in the text. JCBR uses the numbered citation (citation-sequence) method and first six authors, et al. Reference should be in Vancouver style and meet the followings:
Hou WR, Hou YL, Wu GF, Song Y, Su XL, Sun B, et al. cDNA, genomic sequence cloning and overexpression of ribosomal protein gene L9 (rpL9) of the giant panda (Ailuropoda melanoleuca). Genet Mol Res. 2011;10: 1576-1588.
Devaraju P, Gulati R, Antony PT, Mithun CB, Negi VS. Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes. Mol Immunol. 2014 Nov 22. pii: S0161-5890(14)00313-7. doi: 10.1016/j.molimm.2014.11.005
Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: University of Pennsylvania Press; 1992.
Hansen B. New York City epidemics and history for the public. In: Harden VA, Risse GB, editors. AIDS and the historian. Bethesda: National Institutes of Health; 1991. pp. 21-28.
Abbreviations and symbols
Define abbreviations in parenthesis upon first appearance in the text. Use standard abbreviations if they appear at least three times in the text. Keep abbreviations to a minimum and avoid using abbreviations and/or symbols in the title and the abstract. All values of quantities should be given appropriate unit with solidus presentation (mg/ml). Standard abbreviations such as RNA and DNA should not be defined.
Submission Preparation Checklist
We appreciate you for choosing to submit your paper to the Journal of Clinical and Basic Research (JCBR). As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.
- The paper has not been previously published or submitted to another journal for consideration.
- The manuscript must be submitted in English and in Microsoft Word format (DOC, DOCX).
- The text is single-spaced with 12-point New Times Roman.
- All illustrations, figures, and tables are placed within the text at the appropriate places.
- The references have been written in accordance with the format and style provided in the authors’ guideline section.
Changes to authorship
This policy concerns the addition, deletion, or rearrangement of author names in the authorship of accepted manuscripts. Requests to add or remove an author, or to rearrange the author names, must be sent to the Editor from the corresponding author of the accepted manuscript and must include: (a) the reason the name should be added or removed, or the author names rearranged and (b) written confirmation (e-mail, fax, letter) from all authors that they agree with the addition, removal or rearrangement.
Copyright: Accepted manuscripts become the permanent property of the Journal and may not be reproduced, in whole or in part, without the written permission of the Editor. Upon acceptance of an article, the authors will be asked to complete a Journal Publishing Agreement.
Electronic proof will be sent in PDF format to the corresponding author to check for typesetting accuracy. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor errors, no changes will be made in the manuscript at the proof stage. The IJM publisher will do everything to get your article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all of your corrections are sent to us in one communication.
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
All manuscripts must contain the following sections under the heading 'Declarations' (If any of the sections are not relevant to your manuscript, please include the heading and write 'Not applicable' for that section):
Ethics approval and consent to participate
Consent for publication
Availability of data and material
Ethics approval and consent to participate
Manuscripts reporting studies involving human participants, human data or human tissue must include:
- A statement on ethics approval and consent (even where the need for approval was waived)
- The name of the ethics committee that approved the study and the committee’s reference number if appropriate
Studies involving animals must include a statement on ethics approval.
If your manuscript does not report on or involve the use of any animal or human data or tissue, please state “Not applicable” in this section.
Consent for publication
If your manuscript contains any individual person’s data in any form (including individual details, images or videos), consent for publication must be obtained from that person, or in the case of children, their parent or legal guardian. All presentations of case reports must have consent for publication. You can use your institutional consent form or our consent form if you prefer. You should not send the form to us on submission, but we may request to see a copy at any stage (including after publication). If your manuscript does not contain data from any individual person, please state “Not applicable” in this section.
Availability of data and materials
All manuscripts must include an ‘Availability of data and materials’ statement. Data availability statements should include information on where data supporting the results reported in the article can be found including, where applicable, hyperlinks to publicly archived datasets analyzed or generated during the study. By data, we mean the minimal dataset that would be necessary to interpret, replicate and build upon the findings reported in the article. We recognize it is not always possible to share research data publicly, for instance, when individual privacy could be compromised, and in such instances, data availability should still be stated in the manuscript along with any conditions for access. Data availability statements can take one of the following forms (or a combination of more than one if required for multiple datasets):
The datasets generated and/or analyzed during the current study are available in the [NAME] repository, [PERSISTENT WEB LINK TO DATASETS]
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.
All data generated or analyzed during this study are included in this published article [and its supplementary information files].
The datasets generated and/or analyzed during the current study are not publicly available due [REASON WHY DATA ARE NOT PUBLIC] but are available from the corresponding author on reasonable request.
Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.
The data that support the findings of this study are available from [third party name] but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request and with permission of [third party name]. If your manuscript does not contain any data, please state 'Not applicable' in this section.
More examples of template data availability statements, which include examples of openly available and restricted access datasets, are available here.
All financial and non-financial competing interests must be declared in this section. Please use the authors initials to refer to each author's competing interests in this section. If you do not have any competing interests, please state "The authors declare that they have no competing interests" in this section.
All sources of funding for the research reported should be declared. The role of the funding body in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript should be declared.
The individual contributions of authors to the manuscript should be specified in this section. Please use initials to refer to each author's contribution in this section, for example: "FC analyzed and interpreted the patient data regarding the hematological disease and the transplant. RH performed the histological examination of the kidney, and was a major contributor in writing the manuscript. All authors read and approved the final manuscript."